clinical trial · NCT06222892
A Study of Camlipixant in Male and Female Healthy Participants and Participants With Hepatic Impairment Aged 18-75 Years of Age
Bellus Health Inc. - a GSK company·phase1·completed·n = 32
CoughCamlipixant
brief summary
The purpose of this study is to assess the effect of Hepatic impairment (HI) on the Pharmacokinetic (PK) profile and safety of Camlipixant.
started
Feb 2, 2024
primary completion
Dec 17, 2024
completion
Dec 30, 2024
last updated
Jan 7, 2026
official title
A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Safety of Camlipixant in Male and Female Participants Aged 18-75 Years of Age With Hepatic Impairment Compared to Matched Healthy Participants With Normal Hepatic Function
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol